// App-Quantinova.ai

16709 : Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension

Researchers

Presenter

  • Mark Cooper

Principal Investigators

  • Ilkka Tikkanen

  • Susanne Crowe

  • Odd Erik Johansen

  • Soren S. Lund

  • Hans J. Woerle

  • Uli C. Broedl

  • Thomas Hach

Medical Centers

  • Helsinki Univ Central Hosp and Minerva Inst for Med Res, Helsinki, Finland

  • Univ of Toronto-Toronto Western Hosp, Toronto, ON, Canada

  • Baker IDI Heart & Diabetes Institute, Melbourne, Australia

Locations

  • Finland

  • Canada

  • Australia

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Chronic kidney disease

  • Arterial stiffness

  • Type 2 diabetes mellitus

  • Renal disease

  • Hypertension

  • Diabetes

Biomarkers

  • GC Vitamin D Binding Protein

  • Hemoglobin A1c

  • Sex hormone binding globulin

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved